"How much do we have to pay them though to be in a position to do a deal"
A good question. From memory, at the time the amount was considered inconsequential, hence no dollar figure was assigned. However that was when we were capped at $100M. Perhaps at a $20M market cap, the consequences of buying out the relevant IP from tekcyte is consequential to say the least.
Aside from this, I don't get why you're spending your time worry about patent infringements, given Cynata is not near commercialisation, let alone any copycats. If another company were to launch a trial using a very similar/the same method of iPSC derived MSCs, the cost of Cynata launching legal proceedings would be pretty minimal. In addition, the copycat company would face the same roadblocks Cynata has, namely recruiting patients in a timely manner to produce data that is statistically significant.
This is potentially a risk 5 years away, not now, and hopefully by then Cynata have several big-Pharma partners to deter infringers.
CYP Price at posting:
12.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)